Keyphrases
Phase II Study
100%
DNA Repair
100%
BRCA1, BRCA2
100%
Advanced Cancer
100%
Talazoparib
100%
Clinical Benefit
50%
DNA Damage Repair
50%
Clinical Benefit Rate
50%
PARP Inhibitor (PARPi)
50%
PTEN mutation
50%
Patient-derived
25%
Germ Cells
25%
Stable Disease
25%
Reduced Survival
25%
Complete Response
25%
Cancer Cells
25%
Phase II Trial
25%
Partial Response
25%
Molecular Alterations
25%
Time to Progression
25%
Homologous Recombination Repair Pathway
25%
Line of Therapy
25%
Cohort-based
25%
Medicine and Dentistry
DNA Repair
100%
BRCA1
100%
Advanced Cancer
100%
Talazoparib
100%
PARP Inhibitor
50%
Diseases
25%
Germ Cell
25%
Cancer Cell
25%
Somatics
25%
Phase II Trials
25%
Homologous Recombination
25%
Recombination Repair
25%
Biochemistry, Genetics and Molecular Biology
DNA Repair
100%
BRCA1
100%
Poly ADP Ribose Polymerase
50%
Cancer Cell
25%
Germline
25%
Germ Cell
25%
Homologous Recombination
25%
Phase II Trials
25%
Recombination Repair
25%
Pharmacology, Toxicology and Pharmaceutical Science
Advanced Cancer
100%
Talazoparib
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
66%
Diseases
33%
Malignant Neoplasm
33%
Phase II Trials
33%